All
FDA Approves Assay to Determine Eligibility for Tecentriq in Triple-Negative Breast Cancer
March 11th 2019The Food and Drug Administration approved the VENTANA PD-L1 (SP142) Assay as the first companion diagnostic to aid in identifying patients with triple-negative breast cancer who are eligible for treatment with Tecentriq (atezolizumab) plus chemotherapy.
Dealing with Shoulder Pain After Breast Cancer Treatment
March 9th 2019Breast cancer treatment is a life-saver but also can have side effects, including some related to shoulder pain. It is good to start doing the exercises as soon as the doctor recommends it. After that, a regular tune-up with a physical therapist can help.
FDA Approves Tecentriq Combo for Frontline TNBC
March 8th 2019The Food and Drug Administration has granted an accelerated approval to the frontline combination of Tecentriq (atezolizumab) plus Abraxane (nab-paclitaxel) for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC).
FDA Approves Cinvanti Injection for Chemotherapy-Induced Nausea and Vomiting
March 2nd 2019The U.S. Food and Drug Administration has expanded the approval of Cinvanti injectable emulsion to include a two-minute intravenous use for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.